Meet Örn Almarsson, CEO and Co-Founder at Axelyf, an Icelandic American preclinical stage biotechnology company. Together with his team, he develops medicines for inflammatory and autoimmune conditions, with a focus on delivery technologies for RNA therapeutics. An interview brought to you by Luci, co-author of the Synthesis newsletter.
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules